The COA Research and Manufacturing Limited Company (COARMLC) has officially denied claims suggesting that its product, COA-72, is undergoing clinical trials as an anti-HIV drug.
According to the company, a widely circulated report published by the Daily Graphic on Wednesday, July 16, 2025, is inaccurate and does not reflect the facts presented during a recent visit by the ary Select Committee on Health to its facility.
In a statement signed by management and released on Monday, July 28, 2025, COARMLC described the media coverage as misleading and reiterated its commitment to scientific integrity, regulatory procedures, and honest communication with the Ghanaian public and international partners. "The publication misrepresented our position.
Nowhere did we state that COA-72 is in active clinical trials for HIV treatment," the company emphasized. "We are compelled to issue this clarification to prevent the public from being misled and to reaffirm our integrity as a science-driven institution." The controversy arose from a working visit by the ary Select Committee on Health to COARMLC's facility on Monday, July 14, 2025.
